Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Living with a chronic pain condition can make everyday tasks more challenging. For some people in Southern Utah dealing with ...

Dr. Jim Blanton from Blanton Chiropractic stopped by First Look at Four with his patient Ricky Blevins to tell us about ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

When you think of the YMCA, you might think of working out. But the "Y's" Thriver's Club is about more than making your ...

After experiencing cancer himself, one local doctor is preparing to run the 2024 New York City Marathon to raise money and ...

Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical results from two nadunolimab combination therapy trials ...